Funding Opportunity RFA-MH-23-331 from the NIH Guide for Grants and Contracts. The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to assist awardees in launching competitive, independent research careers.

Funding Opportunity RFA-MH-23-270 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-22-220 to comply with DMSP. This FOA supports the development of software to visualize and analyze the data as part of programs of building the informatics infrastructure for the BRAIN Initiative. Other informatics programs include developing data standards that are needed to describe the new experiments that are being created by or used in the BRAIN Initiative ( RFA-MH-19-146 ), and creating the data infrastructures that will house the data from multiple experimental groups ( RFA-MH-19-145 ). Each of the programs is aimed at building an infrastructure that is used by a particular sub-domain of experimentalists rather than building a single all-encompassing informatics infrastructure now. Building the infrastructure one experimental area at a time will ensure that the infrastructure is immediately useful to components of the research community. As our understanding of the brain improves, it may be possible to create linkages between these various sub-domain specific informatics programs. Investigators of the informatics programs should keep that goal in mind and build for the future even though the current efforts are more limited in scope.

Funding Opportunity PAR-23-159 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.

Notice NOT-TR-23-009 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-160 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.

Notice NOT-TR-23-008 from the NIH Guide for Grants and Contracts

Notice NOT-MH-23-205 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-098 from the NIH Guide for Grants and Contracts. 1.The Centers of Excellence in Genomic Science (CEGS) program establishes academic Centers for advanced genome research. Each CEGS award supports a multi-investigator, interdisciplinary team to develop integrated, transformative genomic approaches to address a biomedical problem. A CEGS project will address a critical issue in genomic science, genomic medicine, or computational genomics, proposing a highly innovative solution that would be a major advance. The research will entail substantial risk, balanced by outstanding scientific and management plans and very high potential payoff. A CEGS will focus on the development of novel technological or computational methods for the production or analysis of comprehensive data sets, on a genome-scale biomedical problem, or on other ways to develop and use genomic approaches for understanding biological systems or furthering the application of genomic knowledge, data, and methods towards clinical applications. Each CEGS will nurture genomics by facilitating the interaction of investigators from several disciplines. Along with its scientific goals, CEGS will also expand the pool of genomic scientists and engineers that can use and apply the novel methods, concepts, and knowledge developed by the CEGS by providing education and outreach experiences to scientists at all career levels.

Notice NOT-HD-23-009 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-155 from the NIH Guide for Grants and Contracts. This Notice of Funding Funding Opportunity (NOFO) supports research on expectancy-generating factors and measures of their effects on expectancies and subsequent cancer symptom management outcomes; and research to identify moderators of such expectancy effects. Specifically, this NOFO will solicit mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. Expectancies are defined in this context as beliefs about future outcomes, including ones response to cancer or cancer treatment. Expectancies can be evoked by social, psychological, environmental, and systemic factors. Expectancy effects are the cognitive, behavioral, and biological outcomes caused by expectancies. Expectancy effects can be generated by expectancies held by patients, clinicians, family members, caregivers, and/or dyadic/social networks. Program is particularly interested in applications that enroll individuals and groups from populations historically underrepresented or excluded from biomedical and behavioral research.

Notice NOT-AG-23-019 from the NIH Guide for Grants and Contracts

Notice NOT-MH-23-206 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-163 from the NIH Guide for Grants and Contracts. Reissue of PAR-21-112 to add renewal as an application type in Sections II and V. The specific purpose of this NOFO is to promote the development of a diverse, interdisciplinary workforce needed to conduct translational research on Alzheimer's disease and Alzheimer's-related dementias from target discovery through clinical development. This NOFO will support institutional training programs for predoctoral and postdoctoral level researchers with diverse educational backgrounds (i.e., basic biology, translational and clinical research, data science). The program invites eligible institutions to develop interdisciplinary training programs that will provide trainees with the knowledge and skills in data science, disease biology, behavioral research, and traditional and emerging drug discovery disciplines necessary to conduct rigorous and cutting-edge basic, translational, and clinical research for AD/ADRD.

Funding Opportunity PAR-23-119 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases.

Funding Opportunity PAR-23-154 from the NIH Guide for Grants and Contracts. "This FOA would support development and validation of clinically relevant models of AD/ADRD including post-TBI dementias. Models could include small animals, larger animals, ex vivo models, human iPSCs, or other in vitro models. Validation includes internal, face, construct, and predictive (to the extent possible) validation. Such validations could include looking at underlying mechanism/pathways, functional imaging, behavior, and other cognitive readouts. Independent replication is also encouraged. These models can be developed/validated with the goal of supporting therapy development or better understanding of human disease mechanisms and mechanisms that uncover predisposition to developing neurodegenerative dementias. Either way, it is essential that models reflect the human condition as much as possible. Novel models of complex pathology or comorbid conditions are encouraged. Such models could include multiple manipulations (genetics, environment, lifestyle, age, etc.) to better reflect the complex interaction of risk factors in patients. New models need to be innovative and address a gap in the currently available models."

Notice NOT-DA-23-023 from the NIH Guide for Grants and Contracts

Notice NOT-DA-24-007 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-107 from the NIH Guide for Grants and Contracts

Notice NOT-HG-23-035 from the NIH Guide for Grants and Contracts

Notice NOT-HG-23-034 from the NIH Guide for Grants and Contracts